Current impact in the treatment of advanced hepatocellular carcinoma:The challenge remains  

作　　者：Angelo A de Mattos Cristiane V Tovo Isadora Z Bombassaro Luis F Ferreira 

机构地区：[1]Department of Hepatology,Federal University of Health Sciences of Porto Alegre,Porto Alegre 90050-170,Rio Grande do Sul,Brazil [2]School of Electronics,Electrical Engineering and Computer Science,Queen’s University of Belfast,Belfast BT95BN,Belfast,United Kingdom

出　　处：《World Journal of Gastrointestinal Oncology》2025年第3期479-483,共5页世界胃肠肿瘤学杂志(英文)

摘　　要：Hepatocellular carcinoma remains a significant cause of mortality worldwide,particularly among patients with liver cirrhosis.In most cases,surveillance in cirrhotic patients is neglected,leading to a diagnosis when the neoplasm is at an advanced stage.Within this context,Zhou et al carried out a network metaanalysis to demonstrate the effectiveness of hepatic arterial infusion chemotherapy,concluding that it is a superior approach compared to sorafenib and transarterial chemoembolization in the treatment of advanced hepatocellular carcinoma.Unfortunately,the meta-analysis in question lacks methodological rigor,preventing the authors from making more definitive assertions.Additionally,we understand that transarterial chemoembolization,when properly indicated,is a highly effective therapeutic option,and that sorafenib,given the results of new therapies based on immune checkpoint inhibitors,is no longer the recommended drug for the treatment of these patients.Therefore,we believe the use of hepatic arterial infusion chemotherapy is increasingly limited and lacks strong scientific support.

关 键 词：Hepatocellular carcinoma META-ANALYSIS TREATMENT Liver diseases Liver neoplasms 

分 类 号：R735.7[医药卫生—肿瘤]